CoImmune, Inc. Appoints Michael Fekete and Greg Tibbitts to its Board of Directors

DURHAM, N.C., July 06, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company that will redefine cancer treatment using best-in-class yet more affordable cellular immunotherapies, today announced the appointments of Michael Fekete and Greg Tibbitts, to the Company’s board of directors. Mr. Fekete and Mr. Tibbitts bring with them a wealth of financial, capital markets and strategic expertise, and prior board level experience.

Originally posted here:
CoImmune, Inc. Appoints Michael Fekete and Greg Tibbitts to its Board of Directors

Valneva Strengthens Management Team; Appoints Vincent Dequenne as SVP Operations and Joshua Drumm as VP Investor Relations

Saint-Herblain (France), July 6, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announced today it has appointed Vincent Dequenne as Senior Vice President Operations and Joshua Drumm as Vice President Investor Relations.

Original post:
Valneva Strengthens Management Team; Appoints Vincent Dequenne as SVP Operations and Joshua Drumm as VP Investor Relations

ZEALAND PHARMA A/S – TRANSACTIONS UNDER SHARE REPURCHASE PROGRAM

Company announcement – No. 45/ 2021

Read the original here:
ZEALAND PHARMA A/S - TRANSACTIONS UNDER SHARE REPURCHASE PROGRAM

Monthly information related to total number of voting rights and shares composing the share capital – June 30, 2021

Visit link:
Monthly information related to total number of voting rights and shares composing the share capital – June 30, 2021

Integrity Implants and Fusion Robotics Merge to Form Accelus

Accelus to Offer Procedure-Enabling Technology with the Goal of Making Minimally Invasive Surgery (MIS) the Standard of Care in Spine Accelus to Offer Procedure-Enabling Technology with the Goal of Making Minimally Invasive Surgery (MIS) the Standard of Care in Spine

Read more from the original source:
Integrity Implants and Fusion Robotics Merge to Form Accelus

AIM ImmunoTech to Host Investor Update Webcast on Wednesday, July 14th at 11:00 AM ET

OCALA, Fla., July 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it will host an investor update webcast at 11:00 a.m. Eastern Time on Wednesday, July 14, 2021, to discuss recent accomplishments and upcoming milestones. Investors and other interested parties are invited to submit questions to management prior to the call's start via email to aim@crescendo-ir.com.

Originally posted here:
AIM ImmunoTech to Host Investor Update Webcast on Wednesday, July 14th at 11:00 AM ET

FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin (RTX) For Treatment of the Knee Pain in Osteoarthritis (OA) Patients

SAN DIEGO, July 06, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today that the company has received FDA clearance to proceed with a Phase 2 clinical study of RTX for treating moderate-to-severe osteoarthritis of the knee pain (OAK).

See the original post:
FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin (RTX) For Treatment of the Knee Pain in Osteoarthritis (OA) Patients

Kymera Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional…

WATERTOWN, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the closing of its upsized underwritten public offering of 5,468,250 shares of its common stock at a public offering price of $47.00 per share, which includes 713,250 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $257.0 million.

Link:
Kymera Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional...

Opiant Pharmaceuticals Announces Positive Top-line Results of Confirmatory Pharmacokinetic (PK) Study for OPNT003, Nasal Nalmefene, a Novel…

SANTA MONICA, Calif., July 06, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced positive top-line results from its confirmatory pharmacokinetic (“PK”) study for OPNT003, nasal nalmefene, for opioid overdose.

View original post here:
Opiant Pharmaceuticals Announces Positive Top-line Results of Confirmatory Pharmacokinetic (PK) Study for OPNT003, Nasal Nalmefene, a Novel...

NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors

BELTSVILLE, Md., July 06, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation of a Phase 1/2 clinical trial for NC762, a humanized B7-H4 monoclonal antibody.

Go here to see the original:
NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors